PA
TRIB

Perceptive Advisors’s Trinity Biotech TRIB Stock Holding History

Perceptive Advisors’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,790,000
Closed -$1.86M – 127
2025
Q3 		$1.86M Hold
1,790,000
– – 0.05% 81
2025
Q2 		$1.16M Buy
+1,790,000
New +$1.2M 0.04% 75
2025
Q1 		– Sell
-1,790,000
Closed -$1.58M – 107
2024
Q4 		$1.58M Sell
1,790,000
-10,000
-0.6% -$13.4K 0.04% 87
2024
Q3 		$1.98M Hold
1,800,000
– – 0.04% 94
2024
Q2 		$3.83M Hold
1,800,000
– – 0.09% 84
2024
Q1 		$3.67M Buy
+1,800,000
New +$4.22M 0.06% 95

Other funds holding TRIB

HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return
WN
Williams & Novak Westlake Village, California $151M AUM 27.43% 1-Year Est. Return
MAWA
Moss Adams Wealth Advisors Seattle, Washington $1.37B AUM 19.97% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Becker Capital Management Portland, Oregon $3.4B AUM 24.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Perceptive Advisors's TRIB Position: Q4 2025 in Review

Perceptive Advisors sold out of Trinity Biotech (TRIB) in Q4 2025, closing a stake of 1,790,000 shares — an estimated $1.86M sold.

Perceptive Advisors first reported a position in TRIB in Q1 2024 and held it in 6 quarters. The position peaked at $3.83M in Q2 2024. 27 funds tracked by Wall St. Rank hold TRIB as of Q4 2025.

  • Perceptive Advisors reported no remaining Trinity Biotech position as of Q4 2025 after selling out during the quarter.
  • Perceptive Advisors sold 1,790,000 Trinity Biotech shares in Q4 2025, an estimated $1.86M.
  • Perceptive Advisors first reported a position in Trinity Biotech in Q1 2024 and held it in 6 quarters.
  • Perceptive Advisors's Trinity Biotech position peaked at $3.83M in Q2 2024.
  • 27 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2025.

Based on Perceptive Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.